Sign up to save your podcasts
Or
Share Dr. Joshua Sabari
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dr. Joshua Sabari
Dr. Sabari shares the results of a phase I study of amivantamab and discusses what these results means for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations.
View all episodes
By Ariez PublishingDr. Sabari shares the results of a phase I study of amivantamab and discusses what these results means for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations.